Objective:To observe the Effects of Tibolone and Estradiol/dydrogesterone on Sleep in Perimenopausal Patients.Methods:A total of 68 patients with perimenopausal syndrome treated at Nanping Pucheng Maternal and Child Health Hospital from January 2023 to August 2023 were selected as the study subjects.They were randomly divided into a control group and an observation group,with 34 cases in each group,using a random number table method.The control group received oral tibo-lone,while the observation group received oral compound Estradiol/dydrogesterone tablets,with a treatment duration of three months.The Pittsburgh Sleep Quality Index(PSQI)scores,estrogen levels[(luteinizing hormone(LH),follicle-stimulating hor-mone(FSH),estradiol(E2)],clinical symptoms[Menopausal Quality of Life Scale(MENQOL),modified Kupperman scoring],and adverse reactions were compared before and after treatment.Results:After treatment,both groups showed a decrease in PSQI scores,LH,FSH,and MENQOL scores,as well as a rise in E2 levels compared to before treatment(all P＜0.05).However,there was no statistically significant difference between the control and observation groups after treatment(all P＞0.05).The total inci-dence of adverse reactions between the two groups(5.88％vs.8.82％)was also not statistically significant(P＞0.05).Conclu-sion:Tibolone and Estradiol/dydrogesterone have comparable clinical efficacy in treating perimenopausal syndrome patients,with similar effects on improving sleep,and both treatments demonstrate good safety profiles.
维普
万方数据